International Journal of Clinical Research

Objective: to treat proliferative diabetes retinopathy (PDR) with ranizumab and whole retinal photocoagulation, and analyze the therapeutic effect. Methods: the PDR patients (n = 70) included in this study were all admitted to our hospital from May 2018 to may 2020, and were grouped according to different treatment methods. They were divided into 35 control groups (whole retinal photocoagulation) and 35 experimental groups (ranizumab + whole retinal photocoagulation). The changes of corrected visual acuity, retinal neuroepithelial thickness in macular fovea and incidence of adverse reactions were observed before and after treatment. Results: compared with before treatment, the corrected visual acuity of the patients was improved continuously after 1 week, 4 weeks, 3 months and half a year of treatment, but the corrected visual acuity of the experimental group was higher than that of the control group (P < 0.05); After treatment, compared with that before treatment, the central macular thickness of patients in the experimental group was continuously decreased, but it was significantly lower than that in the control group (P < 0.05); There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion: the application of ranizumab + whole retinal photocoagulation in the treatment of PDR is safe and can effectively improve the visual acuity of patients. The treatment effect is ideal and worthy of promotion.

PDR; Leizumab; Whole Retinal Photocoagulation; Treatment Effect